STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] ELI LILLY & Co SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Lilly Endowment Inc. has filed a Form 144 indicating a planned sale of 310,000 shares of Eli Lilly and Company common stock through J.P. Morgan Securities LLC, with an aggregate market value of 319,315,500. The filing notes that Eli Lilly had 945,383,757 shares outstanding at the time of the notice and lists 11/19/2025 as the approximate sale date on the NYSE or NASDAQ.

The securities to be sold trace back to common stock originally acquired by gift on 02/10/1948 from the J.K. Lilly Sr. Trust, in a transaction involving 38,400,000 shares. The notice also details a series of recent block sales of Eli Lilly common stock by Lilly Endowment Inc., including 351,015 shares sold on 10/01/2025 for 284,653,451.48 and 305,000 shares sold on 11/12/2025 for 308,411,211.50.

By signing, the seller represents that it is not aware of undisclosed material adverse information about Eli Lilly’s current or prospective operations.

Positive
  • None.
Negative
  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filing for LLY disclose?

The Form 144 filing discloses that Lilly Endowment Inc. plans to sell 310,000 shares of Eli Lilly and Company common stock, with an aggregate market value of 319,315,500, through J.P. Morgan Securities LLC.

How many Eli Lilly (LLY) shares are planned to be sold under this Form 144?

The filing states that 310,000 shares of Eli Lilly and Company common stock are planned to be sold, to be executed on or about 11/19/2025 on the NYSE or NASDAQ.

What is the reported market value of the LLY shares in this planned sale?

The Form 144 reports an aggregate market value of 319,315,500 for the 310,000 shares of Eli Lilly and Company common stock to be sold.

How many Eli Lilly (LLY) shares were outstanding at the time of the Form 144 notice?

The filing lists 945,383,757 shares outstanding of Eli Lilly and Company common stock at the time the notice was prepared.

Who is the seller in this LLY Form 144 and how were the shares acquired?

The seller is Lilly Endowment Inc.. The securities to be sold are Eli Lilly common stock that trace back to a gift of 38,400,000 shares acquired on 02/10/1948 from the J.K. Lilly Sr. Trust.

What recent sales of Eli Lilly (LLY) stock by Lilly Endowment Inc. are disclosed?

The filing lists multiple recent sales, including 351,015 shares sold on 10/01/2025 for 284,653,451.48 and 305,000 shares sold on 11/12/2025 for 308,411,211.50, among other transactions over the prior three months.

Does the Form 144 for LLY include any representation about undisclosed adverse information?

Yes. By signing the notice, the seller represents that it does not know any material adverse information about Eli Lilly’s current or prospective operations that has not been publicly disclosed.

Lilly Eli & Co

NYSE:LLY

LLY Rankings

LLY Latest News

LLY Latest SEC Filings

LLY Stock Data

921.91B
943.31M
0.16%
83.87%
0.9%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
INDIANAPOLIS